TP53 and cancer: Nevertheless, it is important to emphasize that ~50% of human cancers harbor p53 deletions and mutations and p53 deficiency in mice is associated with a high frequency of spontaneous cancers [73]; therefore, treatments that interfere with p53 activity should be used only with great caution and for a limited time interval [45,74] (Table 1).